Faculty

Institution

Unit

Venue

Parameswaran Venugopal

Rush University

Affiliations

Division Of Hematology/Oncology/Cell Therapy

Rush University

NoneParameswaran Venugopal is currently serving as a Division Of Hematology/Oncology/Cell Therapy faculty at Rush University.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Parameswaran Venugopal

Rush University

You can click a keyword to filter the displayed items

medicine hematology oncology leukemia hematological malignancies immunology lymphoid neoplasia pharmacology cancer research pharmacotherapy cell biology cell transplantation myeloid neoplasia immunotherapy medicinal research cancer care cancer treatment clinical research cellular therapy stem cell transplantation cell therapy myelodysplastic syndromes tumor biology therapeutic targets experimental medicine malignant blood disorders jama oncology laboratory medicine cancer cells immune responses cytokines cell death oncogenes cell research stem cell research cancer biology lymphatic disease acute myeloid leukemia apoptosis older patients surgical oncology disease progression prognosis hemostasis elderly patients gynecologic oncology metronomic chemotherapy therapeutic efficacy phase 2 modern era chronic lymphocytic leukemia cohort studies anticoagulants novel therapies clinical evidence geriatric medicine clinical therapeutics adult t-cell leukemia-lymphoma clinical gerontology cancer genetics cardiovascular toxicity endocrine-related cancers burkitt lymphoma bone marrow blood transfusion treatment development immunohaematology caching early detection cancer centers arsenic trioxide cd20 antigen expression tumor necrosis factor oral sapacitabine hiv-associated burkitt lymphoma open-label study

Notable Scholarly Works

Notable Federal Grants

Collaborators

233 | S1608: Randomized Phase II Trial Comparing Lenalidomide/Obinutuzumab and Umbralisib/Obinutuzumab With Chemoimmunotherapy in Early Progressing Follicular Lymphoma (Pod24). Hematological Oncology (2025)

hematologymedicineoncologyhematological malignanciesleukemiaimmunotherapylymphoid neoplasiajama oncologypathologyclinical trials

A Multicenter Phase 1/2 Trial of Lenalidomide and Dose-Adjusted Epoch-R in Myc-Associated Dlbcl. Blood Advances (2025)

hematologymedicineoncologyhematological malignanciesmyc-associated dlbcldrug resistanceleukemiamulticenter phase 1/2lymphoid neoplasiapharmacologyapplied pharmacologyexperimental medicinedose-adjusted epoch-rpharmacotherapymolecular medicinepathologyclinical trials

Nivolumab in Combination With R-Chop for Treatment-NaïVe Diffuse Large B-Cell Lymphoma: An Evaluation of Safety and Efficacy. Blood Advances (2025)

hematologycancer immunotherapymedicineoncologyradiation oncologyhematological malignanciesleukemiaimmune checkpoint inhibitorsimmunotherapylymphoid neoplasiajama oncology

Real-World Outcomes of Autologous Cd19-Directed Car T-Cell Therapy in Relapsed/Refractory Large B-Cell Lymphoma: A Single-Center Experience. Blood (2025)

hematologycancer immunotherapycellular therapyhematological malignanciesradiation oncologycell therapyleukemiaimmunotherapylymphoid neoplasiaimmunologycell transplantationsingle-center experiencereal-world outcomes

Acalabrutinib Alone or in Combination With Rituximab for Follicular Lymphoma: An Open‐Label Study. British Journal of Haematology (2024)

Paolo StratiRebecca ChampionMorton ColemanSonali M. SmithParameswaran VenugopalPeter MartinAndrew WoodKara MillerBeth Christian

hematologyhematological malignanciesoncologyopen-label studyhealth sciencesfollicular lymphoma

Real World First-Line Treatment Strategies and Outcomes in Tp53 Mutated and Unmutated Mantle Cell Lymphoma. Blood (2024)

Jie WangJihao ZhouYucai WangJavier L. MunozKevin G. ShimMuhamad Alhaj MoustafaFiras BaidounKaitlin AnnunzioNarendranath EpperlaMichael McLaneYasmin H. KarimiBinh LuuStephen E SpurgeonCheryl ChangZihan WanDiamone GathersEmily R. KingMarcus P. WatkinsNancy L. BartlettChristine E. RyanGenevieve M GerhardPhilippe ArmandAnn S. LaCasceVedha VaddarajuDanielle S WallaceVaishalee P KenkreChase JungeNatalie GroverJorge A FlorindezReem KarmaliAlexander V. StanisicChen ZhangParameswaran VenugopalGrace YingCaitlin GribbinJia RuanNavika D ShuklaSonali M. SmithViktoriya ZeliksonMichael E. WilliamsStefan K. BartaOmar ElghawyJake SchadeRohini NavalekarMatthew MatasarAndrew M EvensAlexey V. DanilovTimothy S. Fenske

hematologyhematological malignancieslymphoid neoplasiaimmunologycancer treatment

A Phase Ib Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With R-Chop in High-Risk Dlbcl. Blood (2023)

Oluwatobi OdetolaShuo MaJane N. WinterBarbara ProIshan RoyPing XieBin ZhangGeorge KoulogeorgasXinlei MiRobert BayerRobert EisnerValerie NelsonHabib ShaikhDean TsarwhasFaisal SaghirParameswaran VenugopalLeo I. GordonReem Karmali

hematologymedicineoncologylaboratory medicineimmunologypharmacologyhigh-risk dlbclphase ib studypreclinical drug evaluationpharmacotherapydrug deliverydrug safety

Ebv-Positive Pcnsl in Older Patients: Incidence, Characteristics, Tumor Pathology, and Outcomes Across a Large Multicenter Cohort. Leukemia & lymphoma/Leukemia and lymphoma (2023)

Prashasti AgrawalKevin A. DavidZhengming ChenSuchitra SundaramSeo-Hyun KimRyan VacaYong LinSamuel SingerMary-Kate MalecekJordan CarterAdam ZayacMyung Sun KimNishitha ReddyDouglas NeyAlma HabibChristopher StrouseJerome GraberVeronika BachanovaSidra SalmanJean A. VendiolaNasheed HossainMazie TsangAjay MajorMaher K. GandhiColm KeaneDavid A. BondMatthew FolstadJulie ChangAngel Mier-HicksPallawi TorkaPriya RajakumarParameswaran VenugopalStephanie BergMichael GlantzSamuel A. GoldlustRahul MatnaniPallavi KumarThomas A. OllilaJohnny CaiStephen E. SpurgeonAlex G. SiegJoseph ClevelandNarendranath EpperlaReem KarmaliSeema NaikSonali M. SmithJames L. RubensteinBrad S. KahlAmy ChadburnAndrew M. EvensPeter Martin

tumor pathologyolder patientsmedicineoncologyebv-positive pcnslcross-sectional studiesgeriatricsclinical epidemiologycohort studiesleukemialarge multicenter cohortgeriatric medicinelymphoid neoplasiarespiratory medicinesurvival analysisneurologyclinical gerontologyhealth sciences

Older Patients With Primary Central Nervous System Lymphoma: Survival and Prognostication Across 20 U.S. Cancer Centers. American Journal of Hematology (2023)

Kevin A. DavidSuchitra SundaramSeo‐Hyun KimRyan VacaYong LinSamuel SingerMary‐Kate MalecekJordan CarterAdam ZayacMyung Sun KimNishitha ReddyDouglas NeyAlma HabibChristopher StrouseJerome GraberVeronika BachanovaSidra SalmanJean Alyxa VendiolaNasheed HossainMazie TsangAjay MajorDavid A. BondPrashasti AgrawalAngel Mier‐HicksPallawi TorkaPriya RajakumarParameswaran VenugopalStephanie BergMichael GlantzSamuel A. GoldlustMatthew FolstadPallavi KumarThomas A. OllilaJohnny CaiStephen SpurgeonAlex SiegJoseph ClevelandJulie ChangNarendranath EpperlaReem KarmaliSeema NaikPeter MartinSonali M. SmithJames RubensteinBrad KahlAndrew M. Evens

hepatologyhematologyolder patientsmedicineoncologyprognosissurvival analysisneurology

P-441 Soluble Urokinase Plasminogen Activator Receptor (Supar) in Patients With Plasma Cell Dyscrasias, a Pilot Study. Clinical Lymphoma Myeloma & Leukemia (2023)

Yashwanth SudhiniBinod DhakalJochen ReiserMehmet AltintasEunsil HahmVasil PeevParameswaran VenugopalAgne Paner

receptorsleukemiaplasma cell dyscrasiaslymphoid neoplasiaimmunologypilot study

1
2
3
4
5
22
10 / page

Parameswaran Venugopal

Rush University

Affiliations

Division Of Hematology/Oncology/Cell Therapy

Rush University

NoneParameswaran Venugopal is currently serving as a Division Of Hematology/Oncology/Cell Therapy faculty at Rush University.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Parameswaran Venugopal

Rush University

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

hematologymedicineoncologyhematological malignanciesleukemiaimmunotherapylymphoid neoplasiajama oncologypathologyclinical trials

A Multicenter Phase 1/2 Trial of Lenalidomide and Dose-Adjusted Epoch-R in Myc-Associated Dlbcl. Blood Advances (2025)

Nivolumab in Combination With R-Chop for Treatment-NaïVe Diffuse Large B-Cell Lymphoma: An Evaluation of Safety and Efficacy. Blood Advances (2025)

hematologycancer immunotherapymedicineoncologyradiation oncologyhematological malignanciesleukemiaimmune checkpoint inhibitorsimmunotherapylymphoid neoplasiajama oncology

Real-World Outcomes of Autologous Cd19-Directed Car T-Cell Therapy in Relapsed/Refractory Large B-Cell Lymphoma: A Single-Center Experience. Blood (2025)

Acalabrutinib Alone or in Combination With Rituximab for Follicular Lymphoma: An Open‐Label Study. British Journal of Haematology (2024)

Paolo StratiRebecca ChampionMorton ColemanSonali M. SmithParameswaran VenugopalPeter MartinAndrew WoodKara MillerBeth Christian

hematologyhematological malignanciesoncologyopen-label studyhealth sciencesfollicular lymphoma

Real World First-Line Treatment Strategies and Outcomes in Tp53 Mutated and Unmutated Mantle Cell Lymphoma. Blood (2024)

hematologyhematological malignancieslymphoid neoplasiaimmunologycancer treatment

A Phase Ib Study to Evaluate the Safety and Efficacy of Nivolumab in Combination With R-Chop in High-Risk Dlbcl. Blood (2023)

hematologymedicineoncologylaboratory medicineimmunologypharmacologyhigh-risk dlbclphase ib studypreclinical drug evaluationpharmacotherapydrug deliverydrug safety

Ebv-Positive Pcnsl in Older Patients: Incidence, Characteristics, Tumor Pathology, and Outcomes Across a Large Multicenter Cohort. Leukemia & lymphoma/Leukemia and lymphoma (2023)

Older Patients With Primary Central Nervous System Lymphoma: Survival and Prognostication Across 20 U.S. Cancer Centers. American Journal of Hematology (2023)

hepatologyhematologyolder patientsmedicineoncologyprognosissurvival analysisneurology

P-441 Soluble Urokinase Plasminogen Activator Receptor (Supar) in Patients With Plasma Cell Dyscrasias, a Pilot Study. Clinical Lymphoma Myeloma & Leukemia (2023)

Yashwanth SudhiniBinod DhakalJochen ReiserMehmet AltintasEunsil HahmVasil PeevParameswaran VenugopalAgne Paner

receptorsleukemiaplasma cell dyscrasiaslymphoid neoplasiaimmunologypilot study

1
2
3
4
5
22
10 / page